Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. J Ann Rheum Dis. 2020;79:685–99.
Article
CAS
PubMed
Google Scholar
Verstappen M, van Mulligen E, de Jong PHP, van der Helm-van Mil AHM. DMARD-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability. RMD Open. 2020;6:1–13.
Article
Google Scholar
Gul H, Harnden K, Saleem BL. Defining the optimal strategies for achieving drug-free remission in rheumatoid arthritis: a narrative review. Healthcare. 2021;9:1–20.
Article
Google Scholar
Filipowicz-Sosnowska A. Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. Reumatologia. 2017;55:284–9.
Article
PubMed
PubMed Central
Google Scholar
Ajeganova S, van Steenbergen HW, van Nies JA, Hamburguesas LE, Huizinga TWJ, van der Helm-van Mil AHM. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2016;75:867–73.
Article
CAS
PubMed
Google Scholar
Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol. 2013;31(Suppl):S4–8.
PubMed
Google Scholar
van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AHM. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis. 2015;74:806–12.
Article
PubMed
Google Scholar
Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58:2958–67.
Article
CAS
PubMed
Google Scholar
Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, van Groenendael JH, Han KH, Kerstens PJ, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70:315–9.
Article
CAS
PubMed
Google Scholar
Kuijper TM, Luime JJ, de Jong PH, Gerards AH, van Zeben D, Tchetverikov I, et al. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Ann Rheum Dis. 2016;75:2119–23.
Article
CAS
PubMed
Google Scholar
Baker KF, Skelton AJ, Lendrem DW, Scadeng A, Thompson B, Pratt AG, et al. Predicting drug-free remission in rheumatoid arthritis: a prospective interventional cohort study. J Autoimmun. 2019;105:1–8.
Article
Google Scholar
van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Helm-van Mil AH, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60:2262–71.
Article
PubMed
Google Scholar
Gul H, Ponchel F, Emery P. In RA patients in remission, which biomarkers predict successful tapering of csDMARDs? Ann Rheum Dis. 2021;80(Suppl 1):110.
Article
Google Scholar
Hughes LD, Done J, Young A. A 5-item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. BMC Musculoskelet Disord. 2013;14:286.
Article
PubMed
PubMed Central
Google Scholar
Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483–503.
Article
PubMed
PubMed Central
Google Scholar
van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337–51.
Article
PubMed
CAS
Google Scholar
Pasma A, van’t Spijker A, Hazes JMW, Busschbach JJV, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43:18–28.
Article
PubMed
Google Scholar
Salt E, Frazier SK. Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature. Orthop Nurs. 2010;29:260–75.
Article
PubMed
PubMed Central
Google Scholar
Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33:901–13.
Article
PubMed
Google Scholar
Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334:248–54.
Article
PubMed
Google Scholar
De Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol. 2010;5:313–26.
Article
Google Scholar
Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. Joint Bone Spine. 2000;67:178–82.
CAS
PubMed
Google Scholar
Contreras-Yañez I, Ponce-De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying anti-rheumatic drugs. Am Med Sci. 2010;340:282–90.
Article
Google Scholar
Contreras-Yáñez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V. Persistence on therapy is a major determinant of patient-, physician-, and laboratory reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010;28:748–51.
PubMed
Google Scholar
Contreras- Yáñez I, Pascual-Ramos V. Predictors of health care dropout in an inception cohort of patients with early-onset rheumatoid arthritis. BMC Musculoskeletal Dis. 2017;18:1–9.
Article
Google Scholar
Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 1999;131(10):768–74.
Article
CAS
PubMed
Google Scholar
Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.
Article
PubMed
Google Scholar
Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995;54(12):944–7.
Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625-36. https://doi.org/10.1002/art.21235.
Gul H, Ferreira J, Emery P. Remission in rheumatoid arthritis: is it all the same? Expert Rev Clin Pharmacol. 2015;8:575–86.
Article
CAS
PubMed
Google Scholar
Prevoo M, van’t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
Article
CAS
PubMed
Google Scholar
Mody G, Cardiel M. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol. 2008;22:621–41.
Article
PubMed
Google Scholar
Massardo L, Pons-Estel B, Wojdyla D, Cardiel M, Galarza-Maldonado C, Furst DE, et al. Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res. 2012;64:1135–43.
Google Scholar
Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44–54.
PubMed
Google Scholar
Deyo R, Inui T, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol. 1981;8:931–6.
CAS
PubMed
Google Scholar
Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int. 2007;27:743–6.
Article
PubMed
Google Scholar
Garcia-Gonzalez A, Richardson M, Popa-Lisseanu M, Cox V, Kallen M, Janssen N. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27:883–9.
Article
PubMed
Google Scholar
Lorish C, Richards B, Brown S. Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care Res. 1990;3:78–84.
CAS
PubMed
Google Scholar
Grijalva C, Chung C, Arbogast P, Stein C, Mitchel E, Griffin M. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45:66–76.
Article
Google Scholar
Curkendall S, Patel V, Gleeson M, Campbell R, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patients out-of-pocket payments matter? Arthritis Rheum. 2008;59:1519–26.
Article
CAS
PubMed
Google Scholar
Hoon L, Pullenayegu E, Moinedding R, Gladman D, Silverman E, Feldman B. Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review and worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatr Rheumatol. 2017;29:15–8.
Google Scholar
Cush J. Early rheumatoid arthritis – is there a window of opportunity? J Rheumatol. 2007;80 Suppl:1–7.
Google Scholar
Contreras-Yáñez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther. 2015;17:1–9.
Article
Google Scholar
Nell V, Machold K, Eberl G, Stamm T, Uffman M, Smolen J. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906–14.
Article
CAS
PubMed
Google Scholar
Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky D, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75:1428–37.
Article
CAS
PubMed
Google Scholar
van den Broek M, Huizinga T, Dijkmans B, Allart C. Drug-free remission: is it already possible? Curr Opin Rheumatol. 2011;23:266–72.
Article
PubMed
Google Scholar
Wabe N, Wiese M. Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. J Eval Clin Pract. 2017;23:486–93.
Article
PubMed
Google Scholar
Seung J, Jung P, Sang-Wong L, Jungski J, Soo-Koon L, Yong-Beom P. Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA). Semin Arthritis Rheum. 2020;50:1414–20.
Article
CAS
Google Scholar
Kuijper T, Lamer-Karnebeek F, Jacobs J, Hazes J, Luime J. Flare rate pn Patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015;42:2012–22.
Article
CAS
PubMed
Google Scholar
O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2010;69:1823–6.
Article
PubMed
CAS
Google Scholar
Lee P, Tan LJ. Drug compliance in outpatients with rheumatoid arthritis. Aust NZ J Med. 1979;9(3):274–7.
Article
CAS
Google Scholar
Kuusalo L, Puolakka K, Kautiainen H, Eklund K, Ilva K, Kaipiainen-Seppänen O, et al. Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Scand J Rheumatol. 2015;44:449–55.
Article
CAS
PubMed
Google Scholar